Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There are
no sensitive and reliable tests to monitor these patients and detect distant metastases before …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

Breast cancer is the most common cancer among women worldwide. Due to its complexity in
nature, effective breast cancer treatment can encounter many challenges. Traditional …

A major contribution to the genome variability among individuals comes from deletions and
duplications—collectively termed copy number variations (CNVs)—which alter the diploid …

Most cancer-related deaths are a result of metastasis, and thus the importance of this
process as a target of therapy cannot be understated. By asking 'how can we effectively treat …

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over
the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a …

Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations
is increasingly used for diagnostic, prognostic and treatment purposes. The genetic profile of …

Background The management of metastatic breast cancer requires monitoring of the tumor
burden to determine the response to treatment, and improved biomarkers are needed …